NCT06631092 — NEC NECVAX neoantigen vaccine trial
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Registry record
| Registry ID | NCT06631092 ↗ |
|---|---|
| Lead sponsor | NEC Bio B.V |
| Collaborators | NEC Bio Therapeutics |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Indication | Triple Negative Breast Cancer |
| Enrollment | 28 participants (target) |
| Start date | 2024-11-20 |
| Primary completion | 2027-12-31 (est.) |
| Last registry update | 26 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06631092), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06631092?
NCT06631092 (Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by NEC Bio B.V.
Is NCT06631092 recruiting?
As of the 2026-05-26 registry update, NCT06631092 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06631092?
The lead sponsor is NEC Bio B.V. Collaborators: NEC Bio Therapeutics.
What condition does NCT06631092 study?
The registered condition is Triple Negative Breast Cancer. Primary completion is listed as 2027-12-31 (estimated).
Are results available for NCT06631092?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06631092.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.